Armata Pharmaceuticals (ARMP) Cash from Investing Activities (2013 - 2026)

Armata Pharmaceuticals has disclosed Cash from Investing Activities across 14 years of filings, most recently posting -$63000.0 for Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at -$63000.0, up 36.36% year-over-year; the trailing twelve-month figure through Mar 2026 was -$506000.0 (up 70.72% YoY), and the FY2025 annual result was -$542000.0, up 71.15% from the prior year.
• Cash from Investing Activities came in at -$63000.0 for Q1 2026 at Armata Pharmaceuticals, down from -$52000.0 in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $455000.0 in Q4 2022 to a low of -$3.5 million in Q3 2023.
• The 5-year median for Cash from Investing Activities is -$242000.0 (2025), against an average of -$754647.1.
• Across the five-year window, Cash from Investing Activities soared 299.56% in 2022 and slumped 751.69% in 2023, its largest moves.
• Armata Pharmaceuticals' Cash from Investing Activities stood at $455000.0 in 2022, then slumped by 625.27% to -$2.4 million in 2023, then surged by 103.22% to $77000.0 in 2024, then tumbled by 167.53% to -$52000.0 in 2025, then declined by 21.15% to -$63000.0 in 2026.
• The last three Cash from Investing Activities figures came in at -$63000.0 (Q1 2026), -$52000.0 (Q4 2025), and -$242000.0 (Q3 2025), per Business Quant data.